经剑突单孔胸腔镜肺叶切除术治疗非小细胞肺癌的临床研究OACSTPCD

Objective:To observe the clinical treatment value of subxiphoid single port video-assisted thoracoscopic surgery(SUVATS)in patients with non-small cell lung cancer(NSCLC).Methods:A total of 121 patients with NSCLC who underwent surgery from Jun.2020 to May 2022 were selected as the study objects,patients who underwent SUVATS were classified as the xiphisternum group(n=53),and those who underwent trans-intercostal single-port thoracoscopic lobectomy were classified as the control group(n=68).Operation time,catheterization time,intraoperative blood loss,hospital stay,pain score,short-term survival rate,and recurrence rate were observed and compared between the two groups.Results:Compared with the control group,the operation time,catheterization time and hospital stay in the xiphisternum group were significantly shorter,the intraoperative blood loss was fewer,and the pain score was lower(P<0.05).The level of serum soluble major histocompatibility complex class-Ⅰ chain associated protein A in the xiphisternum group and the control group at 24 h after operation was significantly lower than that before operation(P<0.05),and that in the xiphi-sternum group was lower than that in the control group(P<0.05).In the xiphisternum group and control group,the total incidence of complications was7.55%and16.18%,the short-term survival rate was 94.34%and 91.18%,and the recurrence rate was 9.43%and 10.29%,respectively,there were no significant differences between the two groups(P>0.05).Conclusions:SUVATS has a good therapeutic effect for NSCLC,can reduce the pain degree of patients,and shorten the rehabilitation process.